WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% – Here’s Why

Posted by Francis Steltz on Sep 4th, 2026

WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report)’s share price traded down 4.3% during mid-day trading on Wednesday . The company traded as low as $4.82 and last traded at $4.7550. Approximately 356,537 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 3,805,564 shares. The stock had previously closed at $4.97.

Analysts Set New Price Targets

Several analysts have weighed in on WVE shares. Wedbush lowered their price target on shares of WAVE Life Sciences from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. B. Riley Financial decreased their price objective on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Mizuho dropped their target price on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Friday, July 17th. Finally, Wells Fargo & Company boosted their price objective on WAVE Life Sciences from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.31.

Read Our Latest Analysis on WVE

WAVE Life Sciences Price Performance

The company has a market capitalization of $926.13 million, a P/E ratio of -4.31 and a beta of -1.30. The company has a 50 day moving average of $5.65 and a 200-day moving average of $7.57.

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $2.27 million during the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. Research analysts predict that WAVE Life Sciences Ltd. will post -1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adrian Rawcliffe sold 12,700 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director owned 44,930 shares in the company, valued at approximately $270,029.30. This trade represents a 13.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 23,564 shares of company stock valued at $132,476 in the last ninety days. 24.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On WAVE Life Sciences

A number of large investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of WAVE Life Sciences by 463.2% during the second quarter. California State Teachers Retirement System now owns 817,769 shares of the company’s stock valued at $4,751,000 after buying an additional 672,563 shares during the period. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences in the second quarter worth about $27,465,000. AlphaGrep UK Ltd purchased a new stake in WAVE Life Sciences in the second quarter worth about $78,000. Seven Fleet Capital Management LP bought a new stake in WAVE Life Sciences during the 2nd quarter valued at approximately $111,000. Finally, AXQ Capital LP boosted its position in WAVE Life Sciences by 301.1% during the 2nd quarter. AXQ Capital LP now owns 63,152 shares of the company’s stock valued at $367,000 after acquiring an additional 47,407 shares in the last quarter. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile

(Get Free Report)

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.